Ortivus: Year-end report January-December 2024

During the year, we have carried out extensive organisational changes and strengthened our team to support our growth journey. Additionally, we have implemented a new business system to improve financial control and the monitoring of our key metrics.

October – December 2024

Net sales increased by 10% and amounted to SEK 21.3 (19.4) million.
The gross margin decreased to 21% (28%).
Adjusted gross margin* amounted to 47% (28%).
EBITDA amounted to SEK -4.4 (-1.2) million.
Adjusted EBITDA* amounted to SEK 2.3 (0.2) million.
Earnings after tax amounted to SEK -9.6 (-2.8) million.
Earnings after tax per share before and after dilution amounted to SEK -0.22 (-0.06).

January – December 2024

Net sales fell by 5% and amounted to SEK 80.4 (84.7) million.
The gross margin amounted to 35% (37%).
Adjusted gross margin* amounted to 42% (37%).
EBITDA amounted to SEK -13.8 (-11.9) million.
Adjusted EBITDA* amounted to SEK -4.9 (-3.7) million.
Profit after tax amounted to SEK -24.9 (-18.2) million.
Profit after tax per share before and after dilution amounted to -0.56 (-0.41) SEK.

Significant events during and after fourth quarter

The exchange transfer to Nasdaq First North Growth Market was carried out on 19 December 2024.
Impairments of inventory, customer projects, and financial assets were carried out during the quarter by SEK 8,5 million which affected the results but not the cash flow.
With the delivery of MobiMed 5 and its integration with the Cambio Cosmic medical record system, a significant step was taken towards providing a comprehensive solution for pre-hospital care.
A new contract was signed after the period with a new customer, East Midlands Ambulance Service NHS Trust (EMAS). The contract strengthens Ortivus presence in the UK and refers to the delivery of a digital system for the management of controlled drugs. The contract is valid for at least three years and is expected to generate revenue of just over SEK 3,6 million.
The current credit framework with its main owner Ponderus Invest AB was extended to 31 December 2026.
In February Gabriel Åhbeck joined as CTO and Emma Mattsson joined as CMO.

About Ortivus

Ortivus develops and commercialises MobiMed, e-health and medical technology solutions for a safer and more efficient healthcare. The company was founded in 1985 and is today a leading provider of mobile digital solutions for prehospital care, worldwide. Ortivus’ innovations are based on in-depth expertise in cardiology as well as decades of development together with users and customers. The company’s headquarters are located in Danderyd, Stockholm. The company has, since 1998, a wholly owned subsidiary based in the United Kingdom and since 2022, a wholly owned subsidiary based in Denmark.

MobiMed is a modular platform that connects and enable real-time information sharing throughout the prehospital care chain. It is currently used by over 12,000 paramedics in over 2,700 emergency vehicles. The platform, MobiMed, consists of several product modules that are completely integrated but can also be used stand-alone. MobiMed comprises four main solutions: MobiMed Monitor, that measures, monitors and shares patients’ vital parameters and ECG in real-time, MobiMed ePR, – an electronic patient record for decision support, collection of patient data and clinical documentation, MobiMed enRoute, – a tool for navigation and case management, and MobiMed Life – a range of stand-alone defibrillators.

MobiMed saves vital seconds and enable healthcare professionals make the right decisions in critical situations. MobiMed also contributes to improved quality of care and saved resources.

Ortivus Class A and Class B shares are listed on Nasdaq First North Growth Market.

Read more about Ortivus at www.ortivus.com

Ortivus Year End Report Q4 2024